Renaissance Technologies’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-321,128
| Closed | -$739K | – | 3614 |
|
|
2023
Q2 | $739K | Buy |
321,128
+46,137
| +17% | +$120K | ﹤0.01% | 2664 |
|
|
2023
Q1 | $833K | Buy |
274,991
+239,855
| +683% | +$677K | ﹤0.01% | 2593 |
|
|
2022
Q4 | $82K | Sell |
35,136
-10,524
| -23% | -$25.2K | ﹤0.01% | 3682 |
|
|
2022
Q3 | $87K | Buy |
+45,660
| New | +$107K | ﹤0.01% | 3637 |
|
|
2021
Q2 | – | Sell |
-1,004,500
| Closed | -$3.35M | – | 3412 |
|
|
2021
Q1 | $3.35M | Buy |
1,004,500
+566,537
| +129% | +$2.19M | ﹤0.01% | 1901 |
|
|
2020
Q4 | $1.55M | Buy |
+437,963
| New | +$1.53M | ﹤0.01% | 2276 |
|
|
2020
Q3 | – | Sell |
-61,207
| Closed | -$111K | – | 3337 |
|
|
2020
Q2 | $111K | Buy |
+61,207
| New | +$100K | ﹤0.01% | 3256 |
|
|
2019
Q4 | – | Sell |
-168,312
| Closed | -$257K | – | 3472 |
|
|
2019
Q3 | $257K | Sell |
168,312
-9,888
| -6% | -$17K | ﹤0.01% | 3076 |
|
|
2019
Q2 | $371K | Buy |
+178,200
| New | +$456K | ﹤0.01% | 3098 |
|
|
2018
Q4 | – | Sell |
-48,766
| Closed | -$461K | – | 3346 |
|
|
2018
Q3 | $461K | Sell |
48,766
-201,886
| -81% | -$2M | ﹤0.01% | 2873 |
|
|
2018
Q2 | $1.83M | Buy |
250,652
+7,152
| +3% | +$42.6K | ﹤0.01% | 2308 |
|
|
2018
Q1 | $1.22M | Sell |
243,500
-159,073
| -40% | -$842K | ﹤0.01% | 2574 |
|
|
2017
Q4 | $2.03M | Buy |
402,573
+241,963
| +151% | +$1.42M | ﹤0.01% | 2338 |
|
|
2017
Q3 | $996K | Sell |
160,610
-49,629
| -24% | -$212K | ﹤0.01% | 2573 |
|
|
2017
Q2 | $757K | Buy |
210,239
+85,666
| +69% | +$295K | ﹤0.01% | 2654 |
|
|
2017
Q1 | $405K | Buy |
124,573
+110,499
| +785% | +$307K | ﹤0.01% | 2830 |
|
|
2016
Q4 | $34K | Sell |
14,074
-102,026
| -88% | -$297K | ﹤0.01% | 3188 |
|
|
2016
Q3 | $399K | Buy |
116,100
+37,885
| +48% | +$148K | ﹤0.01% | 2876 |
|
|
2016
Q2 | $272K | Sell |
78,215
-198,585
| -72% | -$840K | ﹤0.01% | 2971 |
|
|
2016
Q1 | $1.14M | Sell |
276,800
-79,200
| -22% | -$283K | ﹤0.01% | 2518 |
|
|
2015
Q4 | $1.58M | Buy |
356,000
+245,900
| +223% | +$1.35M | ﹤0.01% | 2249 |
|
|
2015
Q3 | $671K | Buy |
+110,100
| New | +$976K | ﹤0.01% | 2536 |
|
|
2015
Q1 | – | Sell |
-26,700
| Closed | -$408K | – | 3136 |
|
|
2014
Q4 | $408K | Buy |
26,700
+3,800
| +17% | +$65.6K | ﹤0.01% | 2491 |
|
|
2014
Q3 | $485K | Sell |
22,900
-127,300
| -85% | -$2.08M | ﹤0.01% | 2317 |
|
|
2014
Q2 | $1.96M | Buy |
150,200
+125,200
| +501% | +$1.78M | ﹤0.01% | 1740 |
|
|
2014
Q1 | $543K | Buy |
+25,000
| New | +$449K | ﹤0.01% | 2327 |
|
Other funds holding ABUS
WCM
TSC
WP
Renaissance Technologies's ABUS Position: Q3 2023 in Review
Renaissance Technologies sold out of Arbutus Biopharma (ABUS) in Q3 2023, closing a stake of 321,128 shares — an estimated $739K sold.
Renaissance Technologies first reported a position in ABUS in Q1 2014 and held it in 26 quarters. The position peaked at $3.35M in Q1 2021. 99 funds tracked by Wall St. Rank hold ABUS as of Q3 2023.
- Renaissance Technologies reported no remaining Arbutus Biopharma position as of Q3 2023 after selling out during the quarter.
- Renaissance Technologies sold 321,128 Arbutus Biopharma shares in Q3 2023, an estimated $739K.
- Renaissance Technologies first reported a position in Arbutus Biopharma in Q1 2014 and held it in 26 quarters.
- Renaissance Technologies's Arbutus Biopharma position peaked at $3.35M in Q1 2021.
- 99 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2023.
Based on Renaissance Technologies's 13F filing for Q3 2023, filed 14 Nov 2023.